Overall verdict
Buy
7.3/10
1-year performance
-5.81%
Score breakdown
Down 5.8% over 1 year, 47% of the 52-week range.
Strongest: Profitability 9.1/10. Weakest: Growth 4.4/10.
15 analysts, target +0.3% vs the price.
HealthEquity, Inc. provides technology-enabled services platforms to consumers and employers in the United States. It offers health savings accounts (HAS); investment platform; online-only automated investment advisory services through Advisor, a Web-based tool. The company also provides flexible spending accounts (FSA) for health and dependent care; health reimbursement arrangements; and Consolidated Omnibus Budget Reconciliation Act continuation services, as well as administers pre-tax commuter benefit programs.
In addition, the company offers HSA and FSA members with access to certain healthcare products, programs, and services through its marketplace. It serves clients through a direct sales force; and brokers and advisors, a network of health plans, benefits administrators, benefits brokers and consultants, and retirement plan record-keepers. HealthEquity, Inc. was incorporated in 2002 and is based in Draper, Utah.
Sector
Health Care
Industry
Health Care Providers and Services
Primary listing
Nasdaq
United States
CEO
Scott Cutler
Founded
2002
Employees
2 814
Revenue / employee
466 748 USD
Next earnings
December 1, 2026 (estimated)
Institutional holders
- BlackRock, Inc.13.44%
- WASATCH ADVISORS LP9.49%
- MORGAN STANLEY5.42%
- VANGUARD PORTFOLIO MANAGEMENT LLC4.83%
- VANGUARD CAPITAL MANAGEMENT LLC4.34%
- STATE STREET CORP3.86%
- GEODE CAPITAL MANAGEMENT, LLC2.83%
- AQR CAPITAL MANAGEMENT LLC2.38%
- DIMENSIONAL FUND ADVISORS LP2.23%
- Other institutions57.91%
494 13F filings as of June 30, 2026: US managers above $100M, filed up to 45 days after quarter end. No insiders, no retail. A share on loan is declared by its lender and by whoever bought it from the short seller, so the total can exceed 100%.
Research uses the underlying stock’s market history. The purchase quote is calculated separately when you review your order.
52-week high
107.62 USD
52-week low
72.76 USD
1-year performance
-5.81%
Declining
Year-to-date performance
-1.45%
Declining
Drawdown
-17.22%
Marked drawdown
Position in the 52-week range
47% of range
Against the world ETF
Over 12 years, from July 2014 to August 2026, the share did not do better than the world ETF once risk is accounted for. It earned more, but shaking 3.3 times harder: for the risk taken, the ETF paid better.
10,000 € placed at the end of July 2014 are worth today
| HealthEquity | 64 013 € |
| World ETF | 41 136 € |
| S&P 500 | 56 709 € |
| Risk-free placement | 10 917 € |
The risk
- Shaking:the share moves 3.3 times as much as the world ETF.
- Worst fall:-60 % between November 2018 and December 2021. 10,000 € placed at the top fell to 3 991 €. The world ETF, at worst: -34 %. Back to its high in 35 months.
HealthEquity earned more than the world ETF since 2014
Value of 10,000 euros placed at the end of July 2014, dividends reinvested, in euros
- HealthEquity: 64 013 €
- World ETF: 41 136 €
- S&P 500: 56 709 €
- Risk-free placement: 10 917 €
Share price without dividends; the world ETF and the index reinvest theirs. A dividend payer is therefore understated here.
Based on past performance. This is not a recommendation.
Range: 105.00 USD - 142.00 USD (2 methods agree)
The price implies growth of 1.51% per year; the company grows at 25.00%.
Gross margin 63.4%, net margin 17.4%, ROIC 7.7%, ROE 11.4%.
Net margin
17.36%
Exceptional
Sector 0.88%|S&P 12.97%
Gross margin
63.41%
Exceptional
Return on equity (ROE)
11.43%
High
Sector 8.69%|S&P 16.52%
Return on invested capital (ROIC)
7.70%
Exceptional
Free cash flow margin (FCF)
35.81%
Exceptional
Profit-to-cash conversion (FCF conversion)
2.06x
High
Margin stability
9.7 pts
Uneven
Revenue to net income
Growth
4.4/10Revenue up 7.6% over 1 year, 12.4% a year over 5, EPS 84.0% a year over 5.
Revenue (trailing 12 months)
1.4Md USD
Revenue growth (1y)
7.65%
Moderate
Revenue growth (3y)
52.41%
Strong
EPS growth (1y)
14.56%
Moderate
EPS CAGR (5y)
83.98%
Exceptional
EPS revisions (3 months)
-0.18%
Revised down
Valuation
7.4/10P/E 32.2x, forward P/E 30.3x, EV/EBITDA 16.0x, PEG 0.38. The multiple sits in the 14th percentile of its own 5-year history.
P/E (TTM)
32.2x
Expensive
Sector 26.2x|S&P 23.0x
Forward P/E
30.3x
Fair
EV / EBITDA
16.0x
Fair
Sector 15.1x|S&P 14.5x
PEG
0.38
Growth unpriced
Sector 0.61|S&P 0.86
Fair value (reverse DCF)
122.49 USD
Undervalued
P/E vs its own 5-year history
among the 14% lowest valuations
Far cheaper than usual
Market cap
7.5Md USD
Financial strength
7.3/10Cash covers 26.4% of the debt, net debt/EBITDA 1.4x.
Net debt / EBITDA
1.4x
Solid
Gearing (net debt / equity)
35.93%
Solid
Cash
256M USD
Cash / market cap
3.42%
Tight
Cash / total debt
26.36%
Tight
Interest coverage
6.7x
Solid
Net debt
715M USD
Equity
2.0Md USD
Closed daily candles, 2 years
Last close on September 24, 2026: 88.60 USD
- MM2094.85
- MM5099.30
- MM20088.89
- RSI 1430.2
Top panel: closed candles, 20, 50 and 200-day moving averages, with volume in grey. Bottom panel: 14-day RSI with dashed 30 and 70 levels.
200-day average slope, 1 month
-0.59%
200-day average slope, 3 months
+0.88%
50-day average slope, 1 month
+2.10%
Price structure
higher-low
Bullish RSI divergence
No
20-day volatility
2.78 % per day
Volatility change
+25.35%
Forecasts by fiscal year
| Fiscal year | EPS | Normalised EPS | Revenue | EBITDA | Net income |
|---|---|---|---|---|---|
| 2027 | 2.94 (12) | 4.72 (14) | 1 417 (14) | 634 (12) | 247 (10) |
Amounts in millions of USD, EPS in USD per share. In brackets, the number of analysts. Consensus as of September 18, 2026.
Same sub-industry: 10 companies behind the medians.
| # | Company | Code | Country | Overall / 10 | Fundamentals / 10 | Mkt cap | P/E | Net margin | Revenue growth | ROIC | Net debt / EBITDA | FCF yield | 1-year perf. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | PGNY | 7.6 | 7.9 | 2.0Md USD | 28.1x | 6.0 % | 5.3 % | 15.5 % | -3.1x | 9.0 % | 20.2 % | ||
| 2 | UNH | 7.6 | 7.1 | 333Md USD | 23.9x | 3.1 % | 0.4 % | 8.4 % | 1.9x | 7.1 % | 7.1 % | ||
| 3 | SAUD3 | 7.4 | 6.5 | 8.0Md USD | 14.3x | 10.6 % | 1213.1 % | 10.4 % | -0.3x | 1.6 % | 5.3 % | ||
| 4 | HQY | 7.3 | 7.0 | 7.5Md USD | 32.2x | 17.4 % | 7.6 % | 7.7 % | 1.4x | 6.5 % | -5.8 % | ||
| 5 | ELV | 6.8 | 6.0 | 86.4Md USD | 17.7x | 2.5 % | 1.4 % | 6.7 % | — | 7.3 % | 22.7 % | ||
| 6 | CNC | 6.2 | 5.4 | 30.7Md USD | Not meaningful (loss) | -2.5 % | 9.9 % | -12.2 % | 1.5x | 29.2 % | 89.2 % | ||
| 7 | HUM | 5.9 | 4.7 | 45.0Md USD | 35.5x | 0.9 % | 26.2 % | 4.1 % | -1.9x | 4.3 % | 47.6 % | ||
| 8 | CLOV | 5.1 | 4.2 | 2.4Md USD | Not meaningful (loss) | -0.7 % | 55.6 % | -5.1 % | 3.5x | 3.1 % | 38.3 % | ||
| 9 | MOH | 4.5 | 2.8 | 9.9Md USD | Not meaningful (loss) | -0.0 % | -4.8 % | -0.1 % | -20.7x | 2.7 % | 6.0 % |
